BPTH earnings analysis
What we found in BPTH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BPTH's latest 10-Q filing reveals a continued struggle with sustaining financial metrics, as the company reported no revenue for the quarters ending March 31 for both 2026 and 2025. Although there was a notable decrease in their net loss and expenses, the lack of revenue generation raises significant concerns about future profitability and operational viability.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Reduced
- Net loss for Q1 2026 was $0.3M, down from $2.9M in Q1 2025.
- Decrease in R&D Expenses
- Research and development expenses were $0.1M in Q1 2026, down from $2.0M in Q1 2025.
- Lower G&A Expenses
- General and administrative expenses fell to $0.3M in Q1 2026, compared to $1.3M in Q1 2025.
- Cash Balance Maintained
- As of March 31, 2026, cash was $0.1M, unchanged from the previous quarter.
- Improvement in EPS
- Net loss per share improved to $(0.03) in Q1 2026 from $(0.40) in Q1 2025.
- Operational Pause Noted
- The company has implemented an operational pause in June 2025 to conserve capital.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependence on Future Funding
- The company’s ability to continue operations is reliant on securing additional funding amidst a cash balance of only $0.1M.
- Clinical Trials on Hold
- All ongoing clinical trials have been paused due to cash flow constraints, potentially delaying product development.
- Operational Inefficiencies
- The furlough of employees may result in reduced operational effectiveness and potential loss of expertise.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
What they said about what is next.
No forward guidance provided regarding revenue expectations.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2025
- Bio-Path reported a Q1 2025 net loss of $2.852 million (basic/diluted loss per share $0.40) versus a $3.157 million loss in Q1 2024 (loss per share $4.88), driven by lower operating expenses and a $0.394 million…
- 10-Q · November 14, 2024
- Bio-Path reported an improved operating and EPS result in Q3: net loss narrowed to $(2,115) for the quarter (vs. $(3,199) in 2023 Q3) and basic net loss per share improved to $(0.70) (vs. $(6.36)). Operating expense…
- 10-Q · August 14, 2024
- Bio-Path’s Q2 2024 results show material operating improvement driven by lower R&D spend and a large non-cash gain on warrant remeasurement, producing a smaller net loss of $(1,869) for the quarter (net loss per share…
- 10-Q · August 14, 2023
- Bio-Path reported no revenue and a deeper quarterly loss as R&D activity ramped: net loss for the three months ended June 30, 2023 was $4,234 (net loss per share $0.53) versus $3,008 ($0.42) in the prior-year quarter.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BPTH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever